ArticlePloS one2012
A p53-Pax2 pathway in kidney development: implications for nephrogenesis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Aberrant centrosome biogenesis disrupts nephron and collecting duct progenitor growth and fate resulting in fibrocystic kidney disease.Development (Cambridge, England) · 2023Article
- A novel missense mutation in GREB1L identified in a three-generation family with renal hypodysplasia/aplasia-3.Orphanet journal of rare diseases · 2022Article
- The Role of PAX2 in Neurodevelopment and Disease.Neuropsychiatric disease and treatment · 2021Review
- Cellular and Molecular Mechanisms of Kidney Development: From the Embryo to the Kidney Organoid.Frontiers in cell and developmental biology · 2020Review
- Investigation of epigenetics in kidney cell biology.Methods in cell biology · 2019Review
- Centrosome amplification disrupts renal development and causes cystogenesis.The Journal of cell biology · 2018Article
- The non-human primate kidney transcriptome in fetal development.Journal of medical primatology · 2018Article
- [Research progress on genetic and epigenetic mechanisms in congenital heart disease].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Review
- PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.Oncogene · 2017Article
- Regulation of kidney development by the Mdm2/Mdm4-p53 axis.Journal of molecular cell biology · 2017Review
- Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface.Oncotarget · 2016Article
- Fibroblast growth factor receptor-Frs2α signaling is critical for nephron progenitors.Developmental biology · 2015Article
- p53 Enables metabolic fitness and self-renewal of nephron progenitor cells.Development (Cambridge, England) · 2015Article
- Lhx4 deficiency: increased cyclin-dependent kinase inhibitor expression and pituitary hypoplasia.Molecular endocrinology (Baltimore, Md.) · 2015Article
- Progenitor cells and podocyte regeneration.Seminars in nephrology · 2014Review
- The MDM2-p53 pathway: multiple roles in kidney development.Pediatric nephrology (Berlin, Germany) · 2014Review
- In situ histone landscape of nephrogenesis.Epigenetics · 2014Article
- The transcription factor p53: not a repressor, solely an activator.Cell cycle (Georgetown, Tex.) · 2014Article
- Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney.Physiological genomics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Congenital reduction in nephron number (renal hypoplasia) is a predisposing factor for chronic kidney disease and hypertension. Despite identification of specific genes and pathways in nephrogenesis, determinants of final nephron endowment are poorly understood. Here, we report that mice with germ-line p53 deletion (p53(-/-)) manifest renal hypoplasia; the phenotype can be recapitulated by conditional deletion of p53 from renal progenitors in the cap mesenchyme (CM(p53-/-)). Mice or humans with germ-line heterozygous mutations in Pax2 exhibit renal hypoplasia. Since both transcription factors are developmentally expressed in the metanephros, we tested the hypothesis that p53 and Pax2 cooperate in nephrogenesis. In this study, we provide evidence for the presence of genetic epistasis between p53 and Pax2: a) p53(-/-) and CM(p53-/-)embryos express lower Pax2 mRNA and protein in nephron progenitors than their wild-type littermates; b) ChIP-Seq identified peaks of p53 occupancy in chromatin regions of the Pax2 promoter and gene in embryonic kidneys; c) p53 binding to Pax2 gene is significantly more enriched in Pax2 -expressing than non-expressing metanephric mesenchyme cells; d) in transient transfection assays, Pax2 promoter activity is stimulated by wild-type p53 and inhibited by a dominant negative mutant p53; e) p53 knockdown in cultured metanephric mesenchyme cells down-regulates endogenous Pax2 expression; f) reduction of p53 gene dosage worsens the renal hypoplasia in Pax2(+/-) mice. Bioinformatics identified a set of developmental renal genes likely to be co-regulated by p53 and Pax2. We propose that the cross-talk between p53 and Pax2 provides a transcriptional platform that promotes nephrogenesis, thus contributing to nephron endowment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.